Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

Bone Marrow Transplantation volume 51, pages 928–932 (2016)Cite this article

Subjects

Abstract

This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT) between 1992 and 2013 and were reported to the French Society of Bone Marrow Transplantation and Cell Therapies registry. The median age at transplant was 63 years. The majority of patients exhibited disease chemosensitivity to salvage treatment (57 complete responses, 30 partial responses, 1 progressive disease and 3 unknown). The most frequent conditioning regimen consisted of BCNU, cytarabine, etoposide, melphalan (BEAM) chemotherapy (93%). With a median follow-up of 54 months, 5-year estimates of overall survival (OS) and progression free survival (PFS) for the entire group were 67 and 54%, respectively. Despite the missing data, in univariate analysis, the number of salvage chemotherapy lines (1–2 versus ⩾3) significantly influenced the OS, unlike the other prognostic factors (stage III–IV at relapse, disease status before ASCT and negative positron emission tomography (PET) scan) encountered in younger patients. In spite of its limitations, this retrospective study with a long-term follow-up suggests that ASCT is a valid treatment option for chemosensitive R/R cHL in selected elderly patients, with an acceptable rate of toxicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Proctor SJ, Wilkinson J, Sieniawski M . Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 2009; 71: 222–232.

    Article  CAS  Google Scholar 

  2. Sjoberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973–2009. Blood 2012; 119: 990–996.

    Article  Google Scholar 

  3. Boll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2013; 31: 4431–4437.

    Article  Google Scholar 

  4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemo-sensitive Hodgkin’s disease: a randomized trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  Google Scholar 

  5. Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s Lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM Study Group. J Clin Oncol 2008; 26: 5980–5987.

    Article  Google Scholar 

  6. de la Rubia J, Saavedra S, Sanz GF, Martin G, Moscardo F, Martinez J et al. Translant-related mortality in patients older than 60 years undergoing autologous hemopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 21–25.

    Article  CAS  Google Scholar 

  7. Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D et al. Autologous stem cell transpalntation in elderly patients (⩾60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow transplantation registry. Haematologica 2008; 93: 1837–1842.

    Article  Google Scholar 

  8. Puig N, Pintilie M, Seshadri T, al-Farsi K, Franke N, Keating A et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin’s ymphoma. BMT 2011; 46: 1339–1344.

    CAS  Google Scholar 

  9. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253.

    Article  CAS  Google Scholar 

  10. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

    Article  Google Scholar 

  11. Fermé C, Bastion Y, Lepage E, Berger F, Brice P, Morel P et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995; 6: 543–549.

    Article  Google Scholar 

  12. Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V et al. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica 2013; 98: 1185–1195.

    Article  CAS  Google Scholar 

  13. Charlson ME, Pompei P, Ales KL, MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.

    Article  CAS  Google Scholar 

  14. Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015; 170: 179–184.

    Article  CAS  Google Scholar 

  15. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221–230.

    Google Scholar 

  16. Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2013; 19: 1740–1744.

    Article  Google Scholar 

  17. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065–1072.

    Article  Google Scholar 

  18. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997; 3: 98–106.

    CAS  PubMed  Google Scholar 

  19. Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica 2012; 97: 1073–1079.

    Article  Google Scholar 

  20. McCarthy PL Jr, Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995–2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013; 19: 1116–1123.

    Article  Google Scholar 

  21. Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2014; 20: 2004–2009.

    Article  Google Scholar 

  22. Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125: 1236–1243.

    Article  CAS  Google Scholar 

  23. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853–1862.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Henri Becquerel, Rouen, France

    A Stamatoullas, S Mareschal & H Tilly

  2. Department of Hematology-Oncology, Hospital Saint Louis, Paris, France

    P Brice

  3. SFGM-TC, Paris, France

    M S Gueye

  4. Department of Clinical Hematology, Nantes University Hospital, Nantes, France

    P Chevallier

  5. Institut Paoli-Calmettes, Marseille, France

    R Bouabdallah

  6. Department of Hematology, Hopital Pitie-Salpetriere, Paris, France

    S Nguyenquoc

  7. Hematology CHU Angers, Angers, France

    S Francois

  8. CHU Dupuytren, Université Limoges, Limoges, France

    P Turlure

  9. Hôpital Lapeyronie, Montpellier, France

    P Ceballos

  10. Service d'Hématologie et Thérapie Cellulaire, CHRU de Tours, Tours, France

    H Monjanel

  11. Division of Hematology, Institut Gustave Roussy, Villejuif, France

    J-H Bourhis

  12. Department of Hematology, Hôpital Augustin Morvan, Brest, France

    G Guillerm

  13. Department of Clinical Hematology, Hôpital Saint-Antoine, Service d’Hématologie Clinique et Thérapie Cellulaire, APHP, Paris, France

    M Mohty

  14. Department of Onco-Hematology, Centre Léon Berard, Lyon, France

    P Biron

  15. Department of Hematology, Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France

    J Cornillon

  16. Lymphoid Malignancies Unit, Hôpital Henri Mondor and Université Paris, Creteil, France

    K Belhadj

  17. Hôpital de Brabois, Vandoeuvre les, Nancy, France

    C Bonmati

  18. Department of Hematology, Hopital Haut-Leveque, Pessac, France

    M-S Dilhuydy

  19. Department of Hematology, University Hospital of Toulouse, Toulouse, France

    A Huynh

  20. CHRU Rennes, Rennes, France

    M Bernard

  21. Department of Hematology, Dijon University Hospital, Dijon, France

    M-L Chrétien

  22. Department of Hematology-Bone Marrow Transplantation, Saint Louis Hospital, Paris, France

    R Peffault de Latour

Authors
  1. A Stamatoullas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Brice
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M S Gueye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Mareschal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Nguyenquoc
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Francois
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Turlure
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Ceballos
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Monjanel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J-H Bourhis
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G Guillerm
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P Biron
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J Cornillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. K Belhadj
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. C Bonmati
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. M-S Dilhuydy
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. A Huynh
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. M Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. M-L Chrétien
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. R Peffault de Latour
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. H Tilly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Stamatoullas.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stamatoullas, A., Brice, P., Gueye, M. et al. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). Bone Marrow Transplant 51, 928–932 (2016). https://doi.org/10.1038/bmt.2016.76

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.76

This article is cited by

Search

Advanced search

Quick links